Clinical trial · no report yet · Phase 2
ROSALINE
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
- NCT04551495 ↗
- Unknown
- Jules Bordet Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer
- Interventions
- Entrectinib; Letrozole; Goserelin
- Arms
- Single Arm · Experimental
- Enrollment
- 65 (estimated)
- Primary outcomes
- Evaluation of the efficacy of endocrine therapy + entrectinib in women with ER+/HER2- early breast cancer of the lobular subtype:Residual Cancer Burden (RCB)
- Sponsor
- Jules Bordet Institute with Hoffmann-La Roche
- Start
- Jan 14, 2021
- Primary completion
- Jan 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04551495 · updated Dec 4, 2024
Publications
linked from the registry- Agostinetto E, Nader-Marta G, Paesmans M, Ameye L, Veys I, Buisseret L, Neven P, Taylor D, Fontaine C, Duhoux FP, Canon JL, Denys H, Coussy F, Chakiba C, Ribeiro JM, Piccart M, Desmedt C, Ignatiadis M, Aftimos P. ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. Future Oncol. 2022 Jul;18(22):2383-2392. doi: 10.2217/fon-2022-0358. Epub 2022 Jun 13. PubMed 35695563
- Okines A, Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, Smith IE, Parton M, Ring A, Johnston S, Turner NC. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Res Treat. 2022 Apr;192(3):563-571. doi: 10.1007/s10549-021-06432-z. Epub 2022 Feb 4. PubMed 35119530